United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer (PFE) gets FDA approval for biosimilar Avastin, Zirabev. This is Pfizer's second oncology biosimilar to be approved in United States.

Pfizer's (PFE) Avastin Biosimilar Zirabev Gets FDA Approval

Pfizer (PFE) presents early data from a study on its investigational gene therapy for DMD. However, the study highlighted some serious side effects in two out of the six participants.

Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study

Shares of Pfizer Inc. PFE, -0.25% ticked up 1.2% in premarket trade Monday after the drugmaker said a Phase 4 study showed that an eczema treatment was well-tolerated in babies between 3 months and two years of age when used over a period of four weeks.

Pfizer stock up 1.2% premarket after drugmaker announces positive results from Phase 4 eczema study

Array's cancer drug pipeline, which has many advanced, high-potential treatments, can boost Pfizer stock price over the long-term.

Acquisition Improves the Outlook of Pfizer Stock

Don't ignore the fallout from Lyrica's loss of patent exclusivity. But do look beyond it.

Pfizer's About to Enter a Sales Slump -- Here's Why You Should Like the Stock Anyway

Sarepta Therapeutics

Pfizer Inc. (NYSE: PFE) has released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy (DMD).

Pfizer’s Duchenne Muscular Dystrophy Pain Could Make Sarepta the DMD King

UnitedHealth Group

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Walgreens

Health-related stocks were among the worst-performing Dow Jones stocks during the first half of 2019, led by Walgreens Boots Alliance.

These Are The 5 Worst Dow Jones Stocks In The First Half Of 2019

Former U.S. Food and Drug Administration Commissioner Scott Gottlieb has joined the board of directors at Pfizer Inc.

Former FDA Commissioner has joined the board of directors at Pfizer Inc.

Pfizer Inc. PFE, +1.02% said Friday the U.S. Food and Drug Administration has approved its oncology biosimilar Zirabev for the treatment of five types of cancer.

Pfizer says FDA has approved its oncology biosimilar Zirabev to treat 5 types of cancer

Pfizer Inc  said on Thursday it has named former U.S. Food and Drug Administration Commissioner Scott Gottlieb to its board of directors, effective immediately.

Pfizer names former FDA chief Scott Gottlieb to its board

Scott Gottlieb, who stepped down as Food and Drug Administration Commissioner in April, will join Pfizer's board of directors, the company announced Thursday.

Former FDA Commissioner Scott Gottlieb joins Pfizer's board of directors

Adverum Biotechnologies

ArQule

Diebold Nixdorf Inc

Enphase Energy

Roku

ZIOPHARM Oncology

Small-cap stocks have under-performed their large cap peers in 2019, but these 7 small-cap stocks have each more than tripled this year.

The 7 Top Small-Cap Stocks Of 2019

As the Dow closes in on records, just four stocks have been shut out of the rally. Some could be on the verge of a major breakout.

UnitedHealth and one other Dow stock could be on the cusp of a comeback

Hershey

TerraForm Power

This drug company, renewable power generator, and candymaker should provide investors with a steady stream of income in the decades to come.

3 Dividend Stocks That Could Pay You the Rest of Your Life

Johnson & Johnson

PFE, JNJ and UNH are three healthcare stocks to buy even up near all-time market highs. Each for its own reasons.

3 Healthcare Stocks to Buy With the Market Near All-Time Highs

BB&T

Centene

Salesforce

Tableau Software

Danaher

First Data

Fiserv

General Electric

Newmont Mining

WellCare Health Plans

The $28 billion acquisition is the eighth-largest bank deal of all time. It’s expected to close in the fourth quarter.

The 7 Best Acquisitions of 2019

Exelixis

Mirati Therapeutics

Around $36 billion worth of biopharma acquisitions over the past few years suggests smaller might be better.

Read This Before You Buy Any New Cancer Drug Stocks

Pfizer's (PFE) PARP inhibitor, Talzenna, receives approval in Europe for treating BRCA-mutated locally advanced or metastatic breast cancer.

Pfizer's Talzenna Gets Approval in Europe for Breast Cancer

CEL-SCI

G1 Therapeutics

These stocks were huge winners last week. But can their momentum continue?

These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?

Dow Inc

The markets have been on a wild ride in this year. The seasonal theme of “Sell in May and go away” passed and seemingly has turned into “Hold your nose and buy in June.

5 Dow Stocks Not Allowing the DJIA a Proper Rally

Pfizer (NYSE:PFE) has received approval from the European Commission for its TALZENNA a breast cancer drug.

Pfizer Receives European Commission Approval For Breast Cancer Drug TALZENNA

GlaxoSmithKline

GlaxoSmithKline has offered concessions to address EU antitrust concerns over its planned joint venture with Pfizer's consumer health business, the European Commission said on Thursday.

GSK offers concessions to address EU concerns over Pfizer deal

Dow Jones component Pfizer could become a leader in colon cancer treatment with its looming $11.4 billion acquisition of biotech company Array BioPharma, an analyst said Wednesday.

Here's Pfizer's Motivation Behind Its Biggest Takeover In 3 Years

Amgen

There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.

News for Pfizer Stock (PFE)